依普罗沙坦（CAS 133040-01-4）：分子式 C23H24N2O4S、分子量 424.5。
| CAS号 | 133040-01-4 |
|---|---|
| 分子式 | C23H24N2O4S |
| 分子量 | 424.5 |
| 熔点 | 248-250 °C (mesylate form) |
| LogP | 3.9 |
| 应用领域 | Uses: MEDICATION、Angiotensin II Type 2 Receptor Blockers、Antihypertensive Agents、Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >25000、exact) in Germany (2009): 33702、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.31、exact) in Germany (2009): 0.41、Excretion rate: 1、Calculated removal (%): 99.9、Methods of Manufacturing: Preparation: J. A. Finkelstein et al.、European Patent Office patent 403159 (1990 to SmithKline Beckman)、eidem、United States of America patent 5185351 (1993 to SmithKline Beecham).、Methyl 4-(bromomethyl)benzoate and 5-chloro-2-propylimidazole are condensed using potassium carbonate in DMF to give the 1-(4-methoxycarbonyl)benzyl derivative of the imidazole (I). I、with the monomethyl ester of 2-thenylmalonate、in a solution of piperidine and pyridine in toluene forms the dimethyl ester of eprosartan、which is saponified to the diacid. The mesylate salt is obtained with methanesulfonic acid.、Eprosartan mesylate、Formulations、Preparations: Table: Eprosartan Mesylate Preparations [Table#7218]、Table: Eprosartan Mesylate Combination Preparations [Table#7219] |
登记用途：Uses: MEDICATION、Angiotensin II Type 2 Receptor Blockers、Antihypertensive Agents、Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >25000、exact) in Germany (2009): 33702、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.31、exact) in Germany (2009): 0.41、Excretion rate: 1、Calculated removal (%): 99.9、Methods of Manufacturing: Preparation: J. A. Finkelstein et al.、European Patent Office patent 403159 (1990 to SmithKline Beckman)、eidem、United States of America patent 5185351 (1993 to SmithKline Beecham).、Methyl 4-(bromomethyl)benzoate and 5-chloro-2-propylimidazole are condensed using potassium carbonate in DMF to give the 1-(4-methoxycarbonyl)benzyl derivative of the imidazole (I). I、with the monomethyl ester of 2-thenylmalonate、in a solution of piperidine and pyridine in toluene forms the dimethyl ester of eprosartan、which is saponified to the diacid. The mesylate salt is obtained with methanesulfonic acid.、Eprosartan mesylate、Formulations、Preparations: Table: Eprosartan Mesylate Preparations [Table#7218]、Table: Eprosartan Mesylate Combination Preparations [Table#7219]。
依普罗沙坦 是一种化工化合物，登记 CAS 号为 133040-01-4，分子式 C23H24N2O4S（分子量 424.5）。
登记 CAS 号：133040-01-4
其分子式 C23H24N2O4S 由 23 个碳、24 个氢、2 个氮、4 个氧、1 个硫 组成。
别名/同义词：依普罗沙坦 · Eprosartan
依普罗沙坦 的 CAS 登记号为 133040-01-4。
分子式 C23H24N2O4S，分子量 424.5。
别名/同义词：依普罗沙坦、Eprosartan。
登记用途：Uses: MEDICATION、Angiotensin II Type 2 Receptor Blockers、Antihypertensive Agents、Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >25000、exact) in Germany (2009): 33702、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.31、exact) in Germany (2009): 0.41、Excretion rate: 1、Calculated removal (%): 99.9、Methods of Manufacturing: Preparation: J. A. Finkelstein et al.、European Patent Office patent 403159 (1990 to SmithKline Beckman)、eidem、United States of America patent 5185351 (1993 to SmithKline Beecham).、Methyl 4-(bromomethyl)benzoate and 5-chloro-2-propylimidazole are condensed using potassium carbonate in DMF to give the 1-(4-methoxycarbonyl)benzyl derivative of the imidazole (I). I、with the monomethyl ester of 2-thenylmalonate、in a solution of piperidine and pyridine in toluene forms the dimethyl ester of eprosartan、which is saponified to the diacid. The mesylate salt is obtained with methanesulfonic acid.、Eprosartan mesylate、Formulations、Preparations: Table: Eprosartan Mesylate Preparations [Table#7218]、Table: Eprosartan Mesylate Combination Preparations [Table#7219]。
依普罗沙坦（CAS 133040-01-4）的独立参考数据，整理自公开化学数据库。
| CAS Registry Number | 133040-01-4 |
|---|---|
| PubChem CID | 5281037 |
| Molecular formula | C23H24N2O4S |
| IUPAC name | 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid |
| UNII (FDA) | 2KH13Z0S0Y |
| Molecular Weight | 424.5 |
|---|---|
| XLogP3 | 4.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Exact Mass | 424.14567842 |
| Monoisotopic Mass | 424.14567842 |
| Topological Polar Surface Area | 121 |
| Heavy Atom Count | 30 |
| Melting Point | 248-250 °C (mesylate form) |
|---|---|
| Melting Point | 260-261 °C |
| Melting Point | 248 - 250 °C (mesylate form) |
| Solubility | 8.66e-03 g/L |
| LogP | 3.9 |
Eprosartan; 133040-01-4; SK&F 108566; SK&F-108566; SKF-108566; 2KH13Z0S0Y; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; CHEBI:4814; SK-108566; DTXSID0022989; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; Eprosartanum
| Reported hazard statements | H315, H319 |
|---|
H315: Causes skin irritation [Warning Skin corrosion/irritation]
H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]
Eprosartan · CAS 133040-01-4 · C23H24N2O4S. UNII 2KH13Z0S0Y. Melting Point: 248-250 °C (mesylate form); Melting Point: 260-261 °C; Melting Point: 248 - 250 °C (mesylate form).
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。
English page: Eprosartan